<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35195049</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1-2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>39</EndPage><MedlinePgn>33-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2041668</ELocationID><Abstract><AbstractText>The absence of disease modifying treatments for amyotrophic lateral sclerosis (ALS) is in large part a consequence of its complexity and heterogeneity. Deep clinical and biological phenotyping of people living with ALS would assist in the development of effective treatments and target specific biomarkers to monitor disease progression and inform on treatment efficacy. The objective of this paper is to present the Comprehensive Analysis Platform To Understand Remedy and Eliminate ALS (CAPTURE ALS), an open and translational platform for the scientific community currently in development. CAPTURE ALS is a Canadian-based platform designed to include participants' voices in its development and through execution. Standardized methods will be used to longitudinally characterize ALS patients and healthy controls through deep clinical phenotyping, neuroimaging, neurocognitive and speech assessments, genotyping and multisource biospecimen collection. This effort plugs into complementary Canadian and international initiatives to share common resources. Here, we describe in detail the infrastructure, operating procedures, and long-term vision of CAPTURE ALS to facilitate and accelerate translational ALS research in Canada and beyond.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Picher-Martel</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5620-6938</Identifier><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Universit&#xe9; Laval, Quebec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Axis, CHU de Qu&#xe9;bec - Universit&#xe9; Laval, Quebec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnussen</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blais</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Axis, CHU de Qu&#xe9;bec - Universit&#xe9; Laval, Quebec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bubela</LastName><ForeName>Tania</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Axis, CHU de Qu&#xe9;bec - Universit&#xe9; Laval, Quebec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, Universit&#xe9; Laval, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Alan C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greiner</LastName><ForeName>Russell</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Computing Science, Faculty of Science, Alberta Machine Intelligence Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine and Dentistry, Alberta Machine Intelligence Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iturria-Medina</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Kelvin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneb</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karamchandani</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Montreal Neurological Institute- Hospital, McGill University Montreal, Qu&#xe9;bec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moradipoor</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>ALS Society of Canada, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vande Velde</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Universit&#xe9; de Montr&#xe9;al, and CHUM Research Center, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunusova</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Speech-Language Pathology, University of Toronto, Toronto, ON, Canada, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupr&#xe9;</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroscience Axis, CHU de Qu&#xe9;bec - Universit&#xe9; Laval, Quebec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, Universit&#xe9; Laval, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CALSNIC</Keyword><Keyword MajorTopicYN="N">CAPTURE</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">open science</Keyword><Keyword MajorTopicYN="N">platform</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35195049</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2041668</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>